Treatment with spironolactone does not seem to be linked with a meaningful increase in risk of cancer occurrence.

• In this systematic review and meta-analysis of 7 observational studies, the pooled occurrence of malignancies, in particular breast and prostate cancers, was determined among those who ever used spironolactone.

• As per observations, spironolactone use was not linked with statistically significant elevated risks of breast or other solid organ cancers.

• It was also found to be linked with a reduced risk of prostate cancer.